[go: up one dir, main page]

DE60131649D1 - Verfahren zur herstellung eines kristalls - Google Patents

Verfahren zur herstellung eines kristalls

Info

Publication number
DE60131649D1
DE60131649D1 DE60131649T DE60131649T DE60131649D1 DE 60131649 D1 DE60131649 D1 DE 60131649D1 DE 60131649 T DE60131649 T DE 60131649T DE 60131649 T DE60131649 T DE 60131649T DE 60131649 D1 DE60131649 D1 DE 60131649D1
Authority
DE
Germany
Prior art keywords
preparing
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131649T
Other languages
English (en)
Other versions
DE60131649T2 (de
Inventor
Hideo Hashimoto
Hideaki Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60131649D1 publication Critical patent/DE60131649D1/de
Publication of DE60131649T2 publication Critical patent/DE60131649T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60131649T 2000-05-15 2001-05-15 Verfahren zur herstellung eines kristalls Expired - Lifetime DE60131649T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000141670 2000-05-15
JP2000141670 2000-05-15
PCT/JP2001/004014 WO2001087874A1 (en) 2000-05-15 2001-05-15 Process for producing crystal

Publications (2)

Publication Number Publication Date
DE60131649D1 true DE60131649D1 (de) 2008-01-10
DE60131649T2 DE60131649T2 (de) 2008-10-30

Family

ID=18648753

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131649T Expired - Lifetime DE60131649T2 (de) 2000-05-15 2001-05-15 Verfahren zur herstellung eines kristalls

Country Status (12)

Country Link
US (4) US7169799B2 (de)
EP (3) EP1293507B1 (de)
KR (2) KR20080067713A (de)
CN (2) CN1280287C (de)
AU (1) AU2001256732A1 (de)
CA (3) CA2701704C (de)
CY (1) CY1107198T1 (de)
DE (1) DE60131649T2 (de)
DK (1) DK1293507T3 (de)
ES (3) ES2521690T3 (de)
PT (1) PT1293507E (de)
WO (1) WO2001087874A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293507B1 (de) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Verfahren zur herstellung eines kristalls
ATE342263T1 (de) * 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
AU2002218506A1 (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP1862456A4 (de) * 2005-03-22 2010-01-27 Daiichi Sankyo Co Ltd Verfahren zur herstellung eines carbapenem derivats mit 1-alkylpyrrolidinstruktur
JPWO2006121151A1 (ja) * 2005-05-13 2008-12-18 第一三共株式会社 １−メチルカルバペネム化合物の結晶
JPWO2006132217A1 (ja) * 2005-06-07 2009-01-08 武田薬品工業株式会社 ベンズイミダゾール化合物の塩の結晶
US20090175959A1 (en) 2005-12-28 2009-07-09 Takeda Pharmaceutical Company Limited Controlled Release Solid Preparation
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
KR20100116165A (ko) * 2007-10-12 2010-10-29 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
US8214093B2 (en) * 2007-11-04 2012-07-03 GM Global Technology Operations LLC Method and apparatus to prioritize transmission output torque and input acceleration for a hybrid powertrain system
EP2227462A1 (de) * 2007-12-31 2010-09-15 Takeda Pharmaceutical Company Limited Kristalline und gelöste formen von (r)-2-[[[3-methyl-4-(2, 2, 2-trifluoroethoxy)-2-pyridinyl-]methyl-]sulfinyl-]-1h-benzoimidazol
ES2638463T3 (es) * 2008-03-10 2017-10-20 Takeda Pharmaceutical Company Limited Cristal de compuesto de bencimidazol
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US20130197232A1 (en) * 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US8853411B2 (en) 2010-03-31 2014-10-07 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
AU2011234001B2 (en) 2010-03-31 2014-08-28 Sun Pharmaceutical Industries Limited Salts of dexlansoprazole and their preparation
US20130243859A1 (en) 2010-12-03 2013-09-19 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
SG190905A1 (en) 2010-12-27 2013-07-31 Takeda Pharmaceutical Orally disintegrating tablet
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CA2840309A1 (en) 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
ES2561098T3 (es) 2011-11-30 2016-02-24 Takeda Pharmaceutical Company Limited Comprimido recubierto en seco
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CA2913106A1 (en) 2013-05-21 2014-11-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablet
DE102014109120B4 (de) 2014-06-30 2017-04-06 Krohne Messtechnik Gmbh Mikrowellenmodul
CN109111430B (zh) * 2017-06-26 2022-09-30 江苏豪森药业集团有限公司 一种右兰索拉唑晶型a及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
JP3929607B2 (ja) 1997-07-23 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体の製造方法
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
WO1999038512A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
CN1087739C (zh) 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2375091A1 (en) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
EP1293507B1 (de) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Verfahren zur herstellung eines kristalls
AU2002218506A1 (en) * 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
WO2007059421A2 (en) * 2005-11-10 2007-05-24 Wyeth Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same

Also Published As

Publication number Publication date
CN1803137A (zh) 2006-07-19
KR101035534B1 (ko) 2011-05-23
US20110257405A1 (en) 2011-10-20
EP1897877A3 (de) 2008-12-10
CN1437592A (zh) 2003-08-20
US20100004458A1 (en) 2010-01-07
EP2281821B1 (de) 2014-10-22
KR20090076980A (ko) 2009-07-13
EP2281821A1 (de) 2011-02-09
CA2701704C (en) 2011-09-06
DE60131649T2 (de) 2008-10-30
KR20080067713A (ko) 2008-07-21
PT1293507E (pt) 2008-01-16
US20070004779A1 (en) 2007-01-04
ES2293988T3 (es) 2008-04-01
US7994332B2 (en) 2011-08-09
CA2762960A1 (en) 2001-11-22
CA2409044C (en) 2013-02-19
ES2511774T3 (es) 2014-10-23
US7569696B2 (en) 2009-08-04
US7169799B2 (en) 2007-01-30
US20030153766A1 (en) 2003-08-14
CY1107198T1 (el) 2012-11-21
EP1897877B1 (de) 2014-09-24
CA2762960C (en) 2014-07-22
CN1280287C (zh) 2006-10-18
EP1293507A4 (de) 2005-09-07
CA2409044A1 (en) 2002-11-14
WO2001087874A1 (en) 2001-11-22
EP1293507A1 (de) 2003-03-19
EP1897877A2 (de) 2008-03-12
ES2521690T3 (es) 2014-11-13
AU2001256732A1 (en) 2001-11-26
US8212046B2 (en) 2012-07-03
EP1293507B1 (de) 2007-11-28
CA2701704A1 (en) 2001-11-22
CN100562318C (zh) 2009-11-25
DK1293507T3 (da) 2007-12-27

Similar Documents

Publication Publication Date Title
DE60131649D1 (de) Verfahren zur herstellung eines kristalls
DE60039268D1 (de) Verfahren zur Herstellung eines TFT
DE60136853D1 (de) Verfahren zur herstellung eines fullerenderivats
ATA10622000A (de) Verfahren zur herstellung eines haarstreifens
DE60142320D1 (de) Verfahren zur Herstellung eines Dünnfilms
DE60019935D1 (de) Verfahren zur herstellung eines grundschmieröls
DE60212699D1 (de) Verfahren zur herstellung eines verbundes
DE60131096D1 (de) Verfahren zur vorbearbeitung eines zylinders
DE60035607D1 (de) Verfahren zur herstellung eines blattförmigen waschmittels
DE60328461D1 (de) Verfahren zur herstellung eines chinazolin-4-onderivats
DE60023415D1 (de) Verfahren zur Herstellung eines Polarisationsbeugungsfilms
DE60112305D1 (de) Verfahren zur herstellung amlodipinmaleat
DE60201421D1 (de) Verfahren zur herstellung eines wachsartigen raffinats
DE50208649D1 (de) Verfahren zur bereitschaftshaltung eines kombikraftwerkes
DE50102299D1 (de) Verfahren zur herstellung des anticholinergikums tiotropiumbromid
DE60114633D1 (de) Verfahren zur herstellung eines polyurethanmaterials
DE60143047D1 (de) Verfahren zur herstellung einer polyisocyanat-zusammensetzung
DE60324671D1 (de) Verfahren zur herstellung eines sulfinyl-acetamids
DE50001155D1 (de) Verfahren zur Herstellung eines Stutzens
DE60122720D1 (de) Verfahren zur herstellung eines vliesstoffes zur polierung
DE69934643D1 (de) Verfahren zur herstellung eines einkristalls mit halbleitender zusammensetzung
DE69938510D1 (de) Verfahren zur herstellung eines einkristallsiliziumkarbids
DE69925721D1 (de) Verfahren zur herstellung eines geschützten 4-aminomethyl-pyrrolidin-3-ons
DE60236171D1 (de) Verfahren for zur herstellung eines 14-hydroxynormorphinon-derivats
DE60000033D1 (de) Verfahren zur Herstellung eines Sol-Gel-Artikels

Legal Events

Date Code Title Description
8364 No opposition during term of opposition